Relay Therapeutics Future Growth
Future criteria checks 2/6
Relay Therapeutics's earnings are forecast to decline at 4.7% per annum while its annual revenue is expected to grow at 53.3% per year. EPS is expected to grow by 4.1% per annum. Return on equity is forecast to be -83.4% in 3 years.
Key information
-4.7%
Earnings growth rate
4.1%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 53.3% |
| Future return on equity | -83.4% |
| Analyst coverage | Good |
| Last updated | 08 Nov 2024 |
Recent future growth updates
Recent updates
Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations
Sep 11Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation
Aug 03
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%
Apr 17Relay Therapeutics: Platform More Important Than Programs
Mar 13Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag
Feb 13Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)
Jan 21We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth
Nov 14Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?
Jun 08Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Feb 22Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Oct 23Relay set to Equal Weight at Barclays; says fairly valued ahead of catalysts
Sep 30Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform
Sep 18Why did Relay Therapeutics stock drop today?
Sep 09Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)
Jan 02Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Reducing Their Forecasts For This Year
Aug 17Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 12 | -453 | -301 | -364 | 8 |
| 12/31/2025 | 1 | -415 | -280 | -329 | 12 |
| 12/31/2024 | 10 | -360 | -218 | -211 | 12 |
| 9/30/2024 | 10 | -345 | -283 | -280 | N/A |
| 6/30/2024 | 35 | -323 | -283 | -281 | N/A |
| 3/31/2024 | 35 | -329 | -287 | -284 | N/A |
| 12/31/2023 | 26 | -342 | -304 | -300 | N/A |
| 9/30/2023 | 26 | -326 | -275 | -268 | N/A |
| 6/30/2023 | 1 | -344 | -267 | -259 | N/A |
| 3/31/2023 | 1 | -323 | -256 | -247 | N/A |
| 12/31/2022 | 1 | -291 | -239 | -229 | N/A |
| 9/30/2022 | 2 | -290 | -220 | -212 | N/A |
| 6/30/2022 | 2 | -267 | -206 | -199 | N/A |
| 3/31/2022 | 2 | -384 | -176 | -170 | N/A |
| 12/31/2021 | 3 | -364 | -78 | -74 | N/A |
| 9/30/2021 | 85 | -261 | -73 | -70 | N/A |
| 6/30/2021 | 84 | -414 | -42 | -41 | N/A |
| 3/31/2021 | 84 | -247 | -35 | -34 | N/A |
| 12/31/2020 | 83 | -230 | -104 | -102 | N/A |
| 9/30/2020 | N/A | -289 | -92 | -90 | N/A |
| 6/30/2020 | N/A | -95 | -88 | -83 | N/A |
| 3/31/2020 | N/A | -86 | -84 | -78 | N/A |
| 12/31/2019 | N/A | -75 | -74 | -66 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RLAY is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RLAY is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RLAY is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RLAY's revenue (53.3% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: RLAY's revenue (53.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RLAY is forecast to be unprofitable in 3 years.